Study: Rivaroxaban improves ACS outcomes

04/22/2013 | TCTMD.com · Healio

Acute coronary syndrome patients who were treated with stents had lower rates of mortality and stent thrombosis on a low-dose regime of rivaroxaban in conjunction with aspirin and clopidogrel, according to the ATLAS ACS 2-TIMI 51 trial involving 15,526 patients. "It is not known whether the observed reduction in stent thrombosis in this study is mediated by a reduction in thrombin generation, which in turn directly mediates stent thrombosis, or alternatively, if the reduction in stent thrombosis is mediated by a reduction in the stimulation of platelet aggregation in so far as thrombin is a potent stimulant of platelets," wrote SCAI fellow Dr. Michael Gibson and colleagues.

View Full Article in:

TCTMD.com · Healio